Eli Lilly (NYSE:LLY) has filed for a six-part note offering, with the aggregate principal amount of the notes offered ...

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...